

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 29D2164544	(X3) Date Survey Completed 09/19/2019
Name of Provider or Supplier Henderson Dermatology & Skin Cancer	Street Address, City, State 2960 St Rose Pkwy, Ste 120, Henderson, NV	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	<p>This Statement of Deficiencies was created as a result of an on-site initial CLIA certification survey conducted at your facility on September 19, 2019. The findings and conclusions of any investigation by the Division of Public and Behavioral Health shall not be construed as prohibiting any criminal or civil investigations, actions or other claims for relief that may be available to any party under applicable federal, state, or local laws.</p>
D5203	<p>SPECIMEN IDENTIFICATION AND INTEGRITY CFR(s): 493.1232</p> <p>The laboratory must establish and follow written policies and procedures that ensure positive identification and optimum integrity of a patient's specimen from the time of collection or receipt of the specimen through completion of testing and reporting of results.</p> <p>This STANDARD is not met as evidenced by: Based on a random audit of laboratory Histopathology patient testing performed on 9/16/19 and an interview with the laboratory regional manager, the laboratory failed to follow the director approved policy and procedure to ensure the positive identification of a patient specimen throughout all phases of laboratory testing. Findings include: 1. The laboratory failed to follow the policy and procedure for positive patient identification throughout the pre-analytic, analytic and post-analytic phases of the laboratory testing process. 2. A patient who had a Mohs procedure performed on 9/16/19 had the diagnosis of Infiltrative Basal Cell Carcinoma indicated on the biopsy report, the Mohs map and the patient final report. The Mohs surgical log on 9/16/19 had the same patient indicating the diagnosis as Infiltrative Squamous Cell Carcinoma. This was confirmed by the regional manager on September 19, 2019 at approximately 10:00 AM. The laboratory performs approximately 500 Histopathology tests annually.</p>